A Body Mass Index of 30 or greater qualifies a patient for Wegovy, while a Body Mass Index of 27 or greater also qualifies them provided at least one diagnosed weight-related condition such as type 2 diabetes, hypertension, or obstructive sleep apnea is present. A licensed prescriber must verify the Body Mass Index number and the qualifying condition before writing the prescription.
Below, the FDA approval thresholds sit alongside how Body Mass Index is calculated, what a clinician actually checks, and what to plan for after the visit.
The FDA-Approved BMI Thresholds for a Wegovy Prescription
Wegovy’s FDA approval sets two specific entry points. Adults with a Body Mass Index of 30 or greater qualify under the obesity category, with no additional diagnosis required. Adults with a Body Mass Index of 27 or greater qualify only when at least one weight-related comorbidity is documented by a healthcare provider.
Those cutoffs trace back to the STEP clinical trial program that Novo Nordisk used to win approval. The trials enrolled adults with a Body Mass Index of 30 or higher, plus a second group at 27 or higher who also had at least one weight-related condition. The FDA built the label around those enrollment criteria, which is why the two thresholds line up exactly with how prescribers screen today.
| Your BMI | Qualifying Factor | Prescription Eligibility |
|---|---|---|
| 30 or greater | None required | Eligible under obesity category |
| 27 to 29.9 | At least one weight-related comorbidity | Eligible with documented diagnosis |
| Below 27 | Any or none | Not eligible, even with a comorbidity |
How Body Mass Index Is Calculated and Which Number Applies to You
Body Mass Index equals your weight in kilograms divided by your height in meters squared. A 5’9″ adult at 203 pounds lands at roughly 30, which clears the obesity threshold without any extra diagnosis. Plug the same height at 183 pounds and the number drops to about 27, where a comorbidity becomes the deciding factor.
The Standard BMI Categories
The CDC adult categories have not changed in decades. Underweight sits below 18.5, normal weight runs from 18.5 to 24.9, overweight covers 25 to 29.9, and obesity begins at 30. Anything beyond 30 splits into class 1 (30 to 34.9), class 2 (35 to 39.9), and class 3 (40 and above), though the prescription rule only cares about the 30 and 27 cutoffs.
Where Small Measurement Differences Come From
Online calculators and clinic scales can disagree by a few tenths of a point. Scale weight, height measurement timing, shoes on or off, and the calculator’s rounding rules feed those gaps. The thresholds themselves stay fixed, so a borderline Body Mass Index near 27 often comes down to the exact number your prescriber records during your visit.
Tip: If your home calculator shows 26.9 and the clinic reads 27.1, the clinic reading is the one that matters for prescribing decisions.
Why Comorbidities Lower the BMI Bar for Wegovy
The comorbidity pathway exists because excess weight rarely travels alone. Type 2 diabetes, hypertension, dyslipidemia, and obstructive sleep apnea all count as qualifying diagnoses at the 27 cutoff, and cardiologists and endocrinologists have pushed for earlier intervention as evidence grows that earlier treatment reduces downstream cardiovascular events.
What Counts as a Documented Diagnosis
A qualifying comorbidity must appear in your medical record with a diagnosis code from a licensed provider. Self-reported symptoms, family history, or a reading from a home blood pressure cuff do not clear the bar on their own. Common lab values such as an A1C of 6.5% or higher, a fasting glucose reading in the diabetic range, or a documented blood pressure above 130/80 give prescribers the clinical evidence they need to record a diagnosis that satisfies the requirement.
- Type 2 diabetes: confirmed through A1C, fasting glucose, or an existing diagnosis in your chart.
- Hypertension: usually documented after multiple elevated readings over weeks or months.
- Dyslipidemia: identified through a standard lipid panel showing abnormal cholesterol or triglycerides.
- Obstructive sleep apnea: typically diagnosed through a sleep study, not just reported snoring.
What a Clinician Actually Evaluates Before Prescribing Wegovy
Confirming the qualifying Body Mass Index is only the opening move. A prescriber also reviews your full medical history, runs baseline labs, and screens for conditions that make semaglutide unsafe before writing anything.
The Standard Prescreening Checklist
- BMI verification: measured height and weight recorded at the visit, not pulled from memory.
- Medical history review: prior pancreatitis, gallbladder disease, kidney function, and any history of eating disorders.
- Comorbidity documentation: existing diagnoses pulled from your chart or confirmed through new lab work.
- Thyroid screening: personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2, both of which disqualify a patient from Wegovy regardless of Body Mass Index.
- Pregnancy check: a negative pregnancy test or confirmation of non-pregnant status before starting, since Wegovy is not approved during pregnancy.
- Concurrent medications: review of other prescriptions, especially insulin or sulfonylureas, which may need adjustment.
Why Diet and Exercise Stay Part of the Plan
The FDA approved Wegovy specifically as an adjunct to a reduced-calorie diet and increased physical activity. That language shapes how prescribers talk about it during visits. Expect your clinician to ask what your current eating pattern looks like, how much activity you get each week, and what changes you are willing to commit to alongside the medication. Lifestyle groundwork also helps insurance reviewers see a serious attempt at weight management before approving coverage.
Meeting the clinical criteria is only half the journey, since coverage decisions can hinge on what payers document next.
Insurance, Cost, and Realistic Next Steps After You Meet the Criteria
Meeting the threshold is the clinical gate. Getting the prescription filled usually runs into a separate hurdle called prior authorization, which is the process your insurer uses to decide whether the medication is medically necessary under your plan.
How Coverage Actually Works
Most plans require documented proof of the qualifying Body Mass Index, a confirmed comorbidity when applicable, and evidence that you have tried lifestyle interventions. Some plans exclude weight-loss medications entirely, regardless of medical need. Coverage for Wegovy is uneven, and approval often depends on your employer’s plan design as much as your clinical picture.
What the Out-of-Pocket Cost Looks Like
Without insurance, the list price for Wegovy often exceeds $1,000 per month. The manufacturer runs a savings program that can bring copays down to $25 or $0 for eligible patients with commercial insurance, but that program excludes those on Medicare, Medicaid, or any government-funded plan. If your Body Mass Index falls short of the 27 or 30 threshold, your clinician may suggest a documented period of lifestyle work, re-evaluation after a recorded weight change, or a discussion of alternative medications that have different eligibility rules.
Even after approval, several boundary situations can derail coverage or require a different application strategy.
Warning: Bring your pharmacy benefit details and any prior authorization requirements to the visit so your prescriber can submit the paperwork before you leave.
Limits and Edge Cases Worth Knowing Before You Apply
The FDA label lists a handful of situations where a Wegovy prescription is unsafe or off-label. Knowing these before your appointment prevents wasted time and helps your prescriber move faster.
Hard Disqualifications
- Personal or family history of medullary thyroid carcinoma: Wegovy carries a boxed warning for this thyroid cancer type, and any personal history disqualifies a patient regardless of Body Mass Index.
- Multiple endocrine neoplasia syndrome type 2: a rare genetic condition that overlaps with the same thyroid cancer risk.
- Pregnancy or planned pregnancy within two months: semaglutide must be discontinued before conception.
- Active pancreatitis: a history of pancreatitis often requires specialist clearance before restarting.
Situations That Need Individualized Assessment
Recent bariatric surgery, gallbladder disease, a history of eating disorders, or significant kidney impairment each require a closer look from your prescriber. None of these rule out Wegovy permanently, but each can change the dosing plan, the monitoring schedule, or whether the medication is the right fit at all.
Why BMI Below 27 Stays Off-Label
Off-label prescribing means using an FDA-approved medication for a reason the label does not cover, and insurers almost never cover that use. Even if a clinician agrees to prescribe Wegovy at a Body Mass Index of 25, the cost falls entirely on you, and the clinical trial data does not support that use. If your weight is genuinely a problem but your number does not clear 27, the better conversation is about lifestyle programs, behavioral therapy, or alternative medications with different eligibility rules.
Pulling these threads together makes it easier to decide where your own situation actually lands.
The Bottom Line
Your path to a Wegovy prescription runs through one of two doors. Either your Body Mass Index sits at 30 or higher, or it sits at 27 or higher with a documented weight-related condition such as type 2 diabetes, hypertension, or sleep apnea. A licensed prescriber confirms the number, runs baseline labs, screens for disqualifying conditions, and then submits the prior authorization that decides whether your insurance covers the cost.
FAQ
What BMI qualifies you for Wegovy?
A Body Mass Index of 30 or greater qualifies you automatically. A Body Mass Index of 27 to 29.9 qualifies you when a healthcare provider has documented at least one weight-related condition such as type 2 diabetes, hypertension, dyslipidemia, or obstructive sleep apnea.
Can you get Wegovy with a BMI of 27?
Yes, if a licensed provider has documented at least one weight-related comorbidity in your medical record. A Body Mass Index of 27 without any qualifying diagnosis does not meet the FDA label, and insurance will not cover off-label use.
Does insurance cover Wegovy based on BMI alone?
No. Insurers also require prior authorization, proof of a documented comorbidity when the number is below 30, and sometimes evidence of prior lifestyle interventions. Coverage varies widely by plan, and some employers exclude weight-loss medications entirely.
Do you need a comorbidity to qualify for Wegovy?
Only if your Body Mass Index falls between 27 and 29.9. A reading of 30 or higher does not require a comorbidity because the obesity category itself satisfies the FDA label.
What is the difference between Wegovy BMI requirements and Ozempic BMI requirements?
Wegovy is FDA-approved specifically for chronic weight management at 27 with a comorbidity or 30 without one. Ozempic shares the same active ingredient, semaglutide, but is FDA-approved for type 2 diabetes, and prescribers use different criteria when Ozempic is prescribed for weight loss off-label.
How do doctors determine Wegovy eligibility?
Doctors measure your height and weight at the visit to confirm Body Mass Index, review your medical record for a qualifying comorbidity when the number is below 30, run baseline labs such as A1C and lipid panels, and screen for personal or family history of medullary thyroid carcinoma before writing the prescription.
